Caitríona Grönberg1, Giuseppe Asciutto2, Ana Persson3, Gunilla Nordin Fredrikson3, Jan Nilsson3, Isabel Gonçalves4, Harry Björkbacka3. 1. Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden. Electronic address: Caitriona.Gronberg@med.lu.se. 2. Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden; Vascular Centre Malmö-Lund, Skåne University Hospital, Lund University, Malmö, Sweden. 3. Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden. 4. Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö, Sweden; Department of Cardiology (Coronary Arteries), Skåne University Hospital, Malmö, Sweden.
Abstract
BACKGROUND AND PURPOSE: Increased interleukin 16 (IL-16) levels in carotid plaques have been associated with reduced incidence of cardiovascular (CV) events during follow-up in patients who underwent carotid endarterectomy (CEA). In the present study we aimed to determine whether high circulating levels of IL-16 also are associated with a decreased risk of CV events after CEA. METHODS: Patients, who had their carotid plaques surgically removed (n=473), were followed for a mean follow-up time of 3.1years. Plasma levels of IL-16 the day before surgery were analyzed by proximity extension assay (PEA) and associated with the occurrence of CV events during follow-up (n=98). RESULTS: High levels of circulating IL-16 were independently associated with a decreased risk of CV events when comparing the highest versus the lowest IL-16 tertile (hazard ratio [HR] 0.47; 95% CI 0.27-0.81; P=0.007), as well as with CV deaths (HR 0.25; 95% CI 0.09-0.70; P=0.008). CONCLUSION: These present findings indicate an association between IL-16 and less clinical complications of atherosclerosis in a population with known advanced carotid disease.
BACKGROUND AND PURPOSE: Increased interleukin 16 (IL-16) levels in carotid plaques have been associated with reduced incidence of cardiovascular (CV) events during follow-up in patients who underwent carotid endarterectomy (CEA). In the present study we aimed to determine whether high circulating levels of IL-16 also are associated with a decreased risk of CV events after CEA. METHODS:Patients, who had their carotid plaques surgically removed (n=473), were followed for a mean follow-up time of 3.1years. Plasma levels of IL-16 the day before surgery were analyzed by proximity extension assay (PEA) and associated with the occurrence of CV events during follow-up (n=98). RESULTS: High levels of circulating IL-16 were independently associated with a decreased risk of CV events when comparing the highest versus the lowest IL-16 tertile (hazard ratio [HR] 0.47; 95% CI 0.27-0.81; P=0.007), as well as with CV deaths (HR 0.25; 95% CI 0.09-0.70; P=0.008). CONCLUSION: These present findings indicate an association between IL-16 and less clinical complications of atherosclerosis in a population with known advanced carotid disease.
Authors: Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer Journal: Oncotarget Date: 2020-09-08
Authors: Parvin Kumar; Miranda Stiernborg; Anna Fogdell-Hahn; Kristoffer Månsson; Tomas Furmark; Daniel Berglind; Philippe A Melas; Yvonne Forsell; Catharina Lavebratt Journal: PLoS One Date: 2022-02-03 Impact factor: 3.240